Lenvatinib Mesylate Intermediate CAS 15568-85-1 Tsarkake> 97.0% (HPLC) Factory

5- (Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion (CAS: 15568-85-1) shine tsaka-tsakin Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib magani ne na ciwon daji na thyroid wanda Eisai Corporation na Japan ya haɓaka (Lambar: E7080), mallakar mai hanawa na tyrosine kinase mai karɓa na baka (RTK) kuma yana iya hana aikin kinase na ƙwararrun ƙwararrun ƙwararrun jijiyoyi (VEGF) masu karɓar VEGFR1 ( FLT1), VEGFR2 (KDR), da VEGFR3 (FLT4).Lenvatinib kuma zai iya hana shigar da sauran RTKs a cikin angiogenesis na pathological, ci gaban tumo, da ci gaban ciwon daji sai dai don ayyukan salula na yau da kullum ciki har da masu karɓar fibroblast girma factor (FGF) FGFR1, 2, 3, da 4;Mai karɓar haɓakar haɓakar platelet (PDGFR [alpha]), KIT, da RET.[Alamomi]: Lenvatinib ya dace da maganin marasa lafiya na ciwon daji na thyroid na sake dawowa gida ko nau'in metastasis, nau'in ci gaba da nau'in rediyoaktif-refractory daban-daban.Ranar 13 ga Fabrairu, 2015, FDA ta Amurka ta amince da Lenvatinib na maganin ciwon daji don maganin ciwon daji na thyroid.Lenvatinib shine mai hanawa enzyme mai yawan manufa, yana da ikon hana VEGFR2 da VEGFR3 (mai karɓar haɓakar haɓakar haɓakar ƙwayoyin jijiyoyi).Sunan kasuwancin Lenvatinib shine Lenvima.A ranar 20 ga Mayu, 2015, Hukumar Kula da Magunguna ta Turai (EMA) ta amince da Lenvatinib don maganin cutar daji, ci gaba a cikin gida ko metastatic bambanta (papillary, follicular, nau'in Hurthle) ciwon daji na thyroid (DTC).A cikin gwajin, lokacin rayuwa na tsaka-tsaki ga marasa lafiya na rediyoaktif iodine-refractory DTC da aka yi wa Lenvatinib ya kasance watanni 18 yayin da ƙimar marasa lafiya da ke ɗaukar placebo shine watanni 3 kawai.